<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897286</url>
  </required_header>
  <id_info>
    <org_study_id>NBTP01</org_study_id>
    <nct_id>NCT00897286</nct_id>
  </id_info>
  <brief_title>Study of Stored Tumor Samples in Young Patients With Brain Tumors</brief_title>
  <official_title>Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas, Medulloblastoma HGNET, CNS Embryonal Tumors and Gliomas of the Pediatric CNS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This laboratory study is looking at stored tumor samples in young patients with brain tumors.&#xD;
      Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors&#xD;
      learn more about changes that occur in DNA and identify biomarkers related to cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this non-therapeutic protocol is to develop and molecularly&#xD;
      characterize patient-derived orthotopic xenografts (PDOXs), organoids and in vitro models&#xD;
      derived from medulloblastomas, High Grade Neuroepithelial Tumors (HGNET), CNS embryonal&#xD;
      tumors, Atypical Teratoid Rhabdoid Tumors (ATRTs), Choroid Plexus Carcinomas (CPCs),&#xD;
      ependymomas, and gliomas. The investigators will characterize the genome-wide mutation,&#xD;
      expression and epigenetic signatures of these models and compare them with the primary tumors&#xD;
      from which they were derived, thus creating a well-characterized and invaluable resource for&#xD;
      research on these rare and deadly pediatric brain tumors. This will also provide important&#xD;
      insights into intratumoral heterogeneity, and molecular abnormalities that may influence the&#xD;
      selective pressures driving evolution, and tumor growth as in PDOXs, organoids or in vitro&#xD;
      cultures and define the relationship between these abnormalities and tumor histologic and&#xD;
      clinical characteristics. This objective will be achieved by applying state-of-the-art DNA,&#xD;
      RNA and epigenome analysis tools to the study of fresh frozen and/or cryopreserved, fixed and&#xD;
      cultured tumor cells, PDOXs and organoids. The establishment of patient-derived orthotopic&#xD;
      xenografts, organoids and cell cultures from each tumor sample will also allow for in vitro&#xD;
      and in vivo analysis of tumor cell growth, signaling and therapeutic response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2004</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between molecular abnormalities and tumor histologic and clinical characteristics</measure>
    <time_frame>20 Years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Tumor/Tissue Sample</arm_group_label>
    <description>Tumor material collected prospectively from a clinically well characterized patient cohort</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fresh frozen, fresh and/or cryopreserved, fixed and cultured tumor cells collected&#xD;
      prospectively from a clinically well characterized patient cohort.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will all brain tumor types will be included with a focus on medulloblastoma,&#xD;
        HGNET, CNS embryonal tumors, gliomas, ependymoma, CPC and ATRT tumors. All studies will be&#xD;
        conducted using tumor material collected prospectively from a clinically well characterized&#xD;
        patient cohort.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Tumor may be primary, progressive or recurrent CNS tumor including brain and/or spine.&#xD;
             All tumor types will be included with a focus on medulloblastoma, HGNET, CNS embryonal&#xD;
             tumors, gliomas, ependymoma, CPC and ATRT tumors. Low grade gliomas are currently very&#xD;
             challenging to culture and implant but if techniques mature these will also be&#xD;
             included. Although rare, patients with ATRT may present with a primary renal and CNS&#xD;
             tumor. In these instances samples will be collected from both the kidney and CNS tumor&#xD;
             for analysis if available.&#xD;
&#xD;
          -  Tumor may be collected at surgery prior to histologic confirmation&#xD;
&#xD;
          -  Age less than 40 years at the time of initial diagnosis.&#xD;
&#xD;
          -  Enrollment in the current version of the institution's banking protocol&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Diagnosis of tumor outside the central nervous system.&#xD;
&#xD;
          -  Age greater than or equal to 40 years at the time of diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Gajjar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tabatha E. Doyle, RN</last_name>
    <phone>901-595-2544</phone>
    <email>tabatha.doyle@stjude.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabatha E. Doyle, RN</last_name>
      <phone>901-595-2544</phone>
      <email>tabatha.doyle@stjude.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood medulloblastoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>gliomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

